Monopar Therapeutics (MNPR) Total Liabilities (2016 - 2026)
Monopar Therapeutics (MNPR) posted Total Liabilities of $2.9 million for Q4 2025, up 9.5% sequentially from $2.6 million in Q3 2025, and down 44.99% YoY from $5.3 million in Q4 2024.
Monopar Therapeutics (MNPR) Total Liabilities (2016 - 2026) Analysis & Trends
Monopar Therapeutics has reported Total Liabilities for 10 years, with the latest figure at $2.9 million in Q4 2025.
- Quarterly Total Liabilities fell 44.99% year-over-year to $2.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.9 million (down 44.99% YoY) and the FY2025 annual result came in at $2.9 million, down 44.99% from the prior year.
- Total Liabilities grew to $2.9 million in Q4 2025 per MNPR's latest filing, from $2.6 million in the prior quarter.
- Over five years, Total Liabilities peaked at $25.9 million in Q1 2021 and troughed at $1.1 million in Q2 2024.
- A 5-year average of $3.2 million and a median of $1.8 million in 2022 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2021 and 2022: Total Liabilities surged 5741.12% in 2021, then tumbled 95.76% in 2022.
- Over 5 years, Total Liabilities stood at $1.6 million in 2021, then soared by 98.5% to $3.1 million in 2022, then tumbled by 43.98% to $1.8 million in 2023, then soared by 198.98% to $5.3 million in 2024, then plunged by 44.99% to $2.9 million in 2025.
- According to Business Quant data, Total Liabilities over the past three periods registered $2.9 million, $2.6 million, and $1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - | 4.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.12 Mn |
| Dec 31, 2025 | 2.89 Mn |
| Sep 30, 2025 | 2.64 Mn |
| Jun 30, 2025 | 1.66 Mn |
| Mar 31, 2025 | 1.49 Mn |
| Dec 31, 2024 | 5.25 Mn |
| Sep 30, 2024 | 1.12 Mn |
| Jun 30, 2024 | 1.09 Mn |
| Mar 31, 2024 | 1.44 Mn |
| Dec 31, 2023 | 1.76 Mn |
| Sep 30, 2023 | 1.98 Mn |
| Jun 30, 2023 | 2.50 Mn |
| Mar 31, 2023 | 2.89 Mn |
| Dec 31, 2022 | 3.14 Mn |
| Sep 30, 2022 | 1.94 Mn |
| Jun 30, 2022 | 2.22 Mn |
| Mar 31, 2022 | 1.10 Mn |
| Dec 31, 2021 | 1.58 Mn |
| Sep 30, 2021 | 1.24 Mn |
| Jun 30, 2021 | 1.10 Mn |